JP2016539174A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539174A5 JP2016539174A5 JP2016536883A JP2016536883A JP2016539174A5 JP 2016539174 A5 JP2016539174 A5 JP 2016539174A5 JP 2016536883 A JP2016536883 A JP 2016536883A JP 2016536883 A JP2016536883 A JP 2016536883A JP 2016539174 A5 JP2016539174 A5 JP 2016539174A5
- Authority
- JP
- Japan
- Prior art keywords
- bromo
- pyridin
- amide
- pentanoic acid
- pyrazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 229910052739 hydrogen Inorganic materials 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 35
- 150000002431 hydrogen Chemical class 0.000 claims description 32
- 125000001153 fluoro group Chemical group F* 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 24
- -1 trifluoromethyl-furanyl Chemical group 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- KTLFYEJQPKLMNG-UHFFFAOYSA-N 2-(6-chloro-5-cyanopyridin-3-yl)-N-(5-chloropyrazin-2-yl)pentanamide Chemical compound ClC=1N=CC(=NC1)NC(C(CCC)C=1C=NC(=C(C1)C#N)Cl)=O KTLFYEJQPKLMNG-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- BSEKSWFNEHTMRZ-UHFFFAOYSA-N 2-(2-bromopyridin-4-yl)-N-(5-bromopyridin-2-yl)pentanamide Chemical compound BrC=1C=CC(=NC1)NC(C(CCC)C1=CC(=NC=C1)Br)=O BSEKSWFNEHTMRZ-UHFFFAOYSA-N 0.000 claims description 2
- WKRVMYCBGJAUHJ-UHFFFAOYSA-N 2-(5-bromopyridin-3-yl)hexanoic acid Chemical compound BrC=1C=C(C=NC1)C(C(=O)O)CCCC WKRVMYCBGJAUHJ-UHFFFAOYSA-N 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- YPDYJHMPMBPEOH-UHFFFAOYSA-N BrC1=CN=C(S1)NC(C(CCC)C1=CC(=NC=C1)OC)=O Chemical compound BrC1=CN=C(S1)NC(C(CCC)C1=CC(=NC=C1)OC)=O YPDYJHMPMBPEOH-UHFFFAOYSA-N 0.000 claims description 2
- DTOFNTWTPRYIOT-UHFFFAOYSA-N BrC=1C=C(C(=NC1)NC(C(CCC)C=1C=NC=C(C1)Br)=O)C Chemical compound BrC=1C=C(C(=NC1)NC(C(CCC)C=1C=NC=C(C1)Br)=O)C DTOFNTWTPRYIOT-UHFFFAOYSA-N 0.000 claims description 2
- LCDFUTBIVFWFJV-UHFFFAOYSA-N BrC=1C=CC(=NC1)NC(C(CCC)N1C=NC(=C1)Br)=O Chemical compound BrC=1C=CC(=NC1)NC(C(CCC)N1C=NC(=C1)Br)=O LCDFUTBIVFWFJV-UHFFFAOYSA-N 0.000 claims description 2
- RCDIPYFRBTYJCL-UHFFFAOYSA-N BrC=1C=CC(=NC1)NC(C(CCC)N1N=C(C(=C1)Br)C#N)=O Chemical compound BrC=1C=CC(=NC1)NC(C(CCC)N1N=C(C(=C1)Br)C#N)=O RCDIPYFRBTYJCL-UHFFFAOYSA-N 0.000 claims description 2
- OCQJSVBETZQHQF-UHFFFAOYSA-N BrC=1C=CC(=NC1)NC(C(CCC)N1N=C(C(=C1)Br)C(F)(F)F)=O Chemical compound BrC=1C=CC(=NC1)NC(C(CCC)N1N=C(C(=C1)Br)C(F)(F)F)=O OCQJSVBETZQHQF-UHFFFAOYSA-N 0.000 claims description 2
- BAVQWUIAXRNFFS-UHFFFAOYSA-N BrC=1C=CC(=NC1F)NC(C(CCC)C=1C=NC=C(C1)Br)=O Chemical compound BrC=1C=CC(=NC1F)NC(C(CCC)C=1C=NC=C(C1)Br)=O BAVQWUIAXRNFFS-UHFFFAOYSA-N 0.000 claims description 2
- QRSZFFSOERLLEZ-UHFFFAOYSA-N BrC=1N=CC(=NC1)NC(=O)C1(CCC1)C=1C=NC=C(C1)Br Chemical compound BrC=1N=CC(=NC1)NC(=O)C1(CCC1)C=1C=NC=C(C1)Br QRSZFFSOERLLEZ-UHFFFAOYSA-N 0.000 claims description 2
- JGGRFADERMYVKX-UHFFFAOYSA-N BrC=1N=CC(=NC1)NC(=O)C1(CCC1)C=1C=NC=C(C1)Cl Chemical compound BrC=1N=CC(=NC1)NC(=O)C1(CCC1)C=1C=NC=C(C1)Cl JGGRFADERMYVKX-UHFFFAOYSA-N 0.000 claims description 2
- NPTMGLDGARTXPX-UHFFFAOYSA-N BrC=1N=CC(=NC1)NC(C(CCC)C1=CC(=NC=C1)Br)=O Chemical compound BrC=1N=CC(=NC1)NC(C(CCC)C1=CC(=NC=C1)Br)=O NPTMGLDGARTXPX-UHFFFAOYSA-N 0.000 claims description 2
- DXHYVDGPCTXALT-UHFFFAOYSA-N BrC=1N=CC(=NC1)NC(C(CCC)C1=CC(=NC=C1)Cl)=O Chemical compound BrC=1N=CC(=NC1)NC(C(CCC)C1=CC(=NC=C1)Cl)=O DXHYVDGPCTXALT-UHFFFAOYSA-N 0.000 claims description 2
- LNJCEFMDTAPKTL-UHFFFAOYSA-N BrC=1N=CC(=NC1)NC(C(CCC)C1=CC(=NC=C1)OC)=O Chemical compound BrC=1N=CC(=NC1)NC(C(CCC)C1=CC(=NC=C1)OC)=O LNJCEFMDTAPKTL-UHFFFAOYSA-N 0.000 claims description 2
- MCUCBNIVAOHWDJ-UHFFFAOYSA-N BrC=1N=CC(=NC1)NC(C(CCC)C=1C=NC(=C(C1)C#N)Cl)=O Chemical compound BrC=1N=CC(=NC1)NC(C(CCC)C=1C=NC(=C(C1)C#N)Cl)=O MCUCBNIVAOHWDJ-UHFFFAOYSA-N 0.000 claims description 2
- YDOCMFIMYJYYNA-UHFFFAOYSA-N BrC=1N=CC(=NC1)NC(C(CCC)C=1C=NC=C(C1)Cl)=O Chemical compound BrC=1N=CC(=NC1)NC(C(CCC)C=1C=NC=C(C1)Cl)=O YDOCMFIMYJYYNA-UHFFFAOYSA-N 0.000 claims description 2
- OWZKPJVKAKYSNY-UHFFFAOYSA-N BrC=1N=CC(=NC1)NC(C(CCC)N1N=C(C(=C1)Br)C#N)=O Chemical compound BrC=1N=CC(=NC1)NC(C(CCC)N1N=C(C(=C1)Br)C#N)=O OWZKPJVKAKYSNY-UHFFFAOYSA-N 0.000 claims description 2
- SQAOZXHTWLSTSH-UHFFFAOYSA-N BrC=1N=CC(=NC1)NC(C(CCC)N1N=C(C(=C1)Br)C)=O Chemical compound BrC=1N=CC(=NC1)NC(C(CCC)N1N=C(C(=C1)Br)C)=O SQAOZXHTWLSTSH-UHFFFAOYSA-N 0.000 claims description 2
- OHXFHRXHMDGRMR-UHFFFAOYSA-N BrC=1N=CC(=NC1)NC(C(CCC)N1N=C(C=C1)C1=CC=C(C=C1)OC)=O Chemical compound BrC=1N=CC(=NC1)NC(C(CCC)N1N=C(C=C1)C1=CC=C(C=C1)OC)=O OHXFHRXHMDGRMR-UHFFFAOYSA-N 0.000 claims description 2
- MMEJPOHDPORNIG-UHFFFAOYSA-N BrC=1N=CC(=NC1)NC(C(CCCC)C=1C=NC=C(C1)Br)=O Chemical compound BrC=1N=CC(=NC1)NC(C(CCCC)C=1C=NC=C(C1)Br)=O MMEJPOHDPORNIG-UHFFFAOYSA-N 0.000 claims description 2
- ADGANLXPAZULQT-UHFFFAOYSA-N C(C)(C)(C)C1=NOC(=C1)NC(C(CCC)C=1C=NC=C(C1)Br)=O Chemical compound C(C)(C)(C)C1=NOC(=C1)NC(C(CCC)C=1C=NC=C(C1)Br)=O ADGANLXPAZULQT-UHFFFAOYSA-N 0.000 claims description 2
- LDNWNHBEQBQMIK-UHFFFAOYSA-N ClC=1C=CC(=NC1)NC(C(CCC)(F)C=1C=NC=C(C1)Br)=O Chemical compound ClC=1C=CC(=NC1)NC(C(CCC)(F)C=1C=NC=C(C1)Br)=O LDNWNHBEQBQMIK-UHFFFAOYSA-N 0.000 claims description 2
- OMNJUUDILUJWHQ-UHFFFAOYSA-N ClC=1C=CC(=NC1)NC(C(CCC)C1=CC(=NC=C1)Br)=O Chemical compound ClC=1C=CC(=NC1)NC(C(CCC)C1=CC(=NC=C1)Br)=O OMNJUUDILUJWHQ-UHFFFAOYSA-N 0.000 claims description 2
- ZSVXIICENQXUJY-UHFFFAOYSA-N ClC=1N=CC(=NC1)NC(C(CCC)C=1C=NC(=C(C1)C#N)C=1C=NN(C1)C)=O Chemical compound ClC=1N=CC(=NC1)NC(C(CCC)C=1C=NC(=C(C1)C#N)C=1C=NN(C1)C)=O ZSVXIICENQXUJY-UHFFFAOYSA-N 0.000 claims description 2
- OOQPFHQGGVMYHP-UHFFFAOYSA-N ClC=1N=CC(=NC1)NC(C(CCC)C=1C=NC(=C(C1)C)Cl)=O Chemical compound ClC=1N=CC(=NC1)NC(C(CCC)C=1C=NC(=C(C1)C)Cl)=O OOQPFHQGGVMYHP-UHFFFAOYSA-N 0.000 claims description 2
- WUEWKNPMKKETRQ-UHFFFAOYSA-N ClC=1N=CC(=NC1)NC(C(CCC)C=1C=NC(=C(C1)F)C=1C=NN(C1)C)=O Chemical compound ClC=1N=CC(=NC1)NC(C(CCC)C=1C=NC(=C(C1)F)C=1C=NN(C1)C)=O WUEWKNPMKKETRQ-UHFFFAOYSA-N 0.000 claims description 2
- LMYXSQZRKZEPAL-UHFFFAOYSA-N ClC=1N=CC(=NC1)NC(C(CCC)C=1C=NC=C(C1)Br)=O Chemical compound ClC=1N=CC(=NC1)NC(C(CCC)C=1C=NC=C(C1)Br)=O LMYXSQZRKZEPAL-UHFFFAOYSA-N 0.000 claims description 2
- MGPAFSPZVRWAPY-UHFFFAOYSA-N ClC=1N=CC(=NC1)NC(C(CCC)C=1C=NC=C(C1)Cl)=O Chemical compound ClC=1N=CC(=NC1)NC(C(CCC)C=1C=NC=C(C1)Cl)=O MGPAFSPZVRWAPY-UHFFFAOYSA-N 0.000 claims description 2
- VGEGTVCXAIOATC-UHFFFAOYSA-N FC=1C=CC(=NC1)NC(C(CCC)C=1C=NC=C(C1)Br)=O Chemical compound FC=1C=CC(=NC1)NC(C(CCC)C=1C=NC=C(C1)Br)=O VGEGTVCXAIOATC-UHFFFAOYSA-N 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- JWSFGKPGNWBYDR-UHFFFAOYSA-N N-(5-bromo-3-fluoropyridin-2-yl)-2-(5-bromopyridin-3-yl)-3-methylbutanamide Chemical compound BrC=1C=C(C(=NC1)NC(C(C(C)C)C=1C=NC=C(C1)Br)=O)F JWSFGKPGNWBYDR-UHFFFAOYSA-N 0.000 claims description 2
- ODXHBGRQUBGEBY-UHFFFAOYSA-N N-(5-bromopyrazin-2-yl)-2,2-dicyclohexylacetamide Chemical compound BrC=1N=CC(=NC1)NC(C(C1CCCCC1)C1CCCCC1)=O ODXHBGRQUBGEBY-UHFFFAOYSA-N 0.000 claims description 2
- XJYNOWSRUYMLTM-UHFFFAOYSA-N N-(5-bromopyrazin-2-yl)-2-(6-bromopyridin-2-yl)pentanamide Chemical compound BrC=1N=CC(=NC1)NC(C(CCC)C1=NC(=CC=C1)Br)=O XJYNOWSRUYMLTM-UHFFFAOYSA-N 0.000 claims description 2
- YUGDWXFUHYAART-UHFFFAOYSA-N N-(5-bromopyrazin-2-yl)-2-(6-chloro-5-fluoropyridin-3-yl)pentanamide Chemical compound BrC=1N=CC(=NC1)NC(C(CCC)C=1C=NC(=C(C1)F)Cl)=O YUGDWXFUHYAART-UHFFFAOYSA-N 0.000 claims description 2
- QVALLEMRNVNBSW-UHFFFAOYSA-N N-(5-bromopyrazin-2-yl)-2-[4-(4-methoxyphenyl)-3-(trifluoromethyl)pyrazol-1-yl]pentanamide Chemical compound BrC=1N=CC(=NC1)NC(C(CCC)N1N=C(C(=C1)C1=CC=C(C=C1)OC)C(F)(F)F)=O QVALLEMRNVNBSW-UHFFFAOYSA-N 0.000 claims description 2
- KQDGBKKGKDZAKF-UHFFFAOYSA-N N-(5-bromopyrazin-2-yl)-2-[4-bromo-3-(trifluoromethyl)pyrazol-1-yl]pentanamide Chemical compound BrC=1N=CC(=NC1)NC(C(CCC)N1N=C(C(=C1)Br)C(F)(F)F)=O KQDGBKKGKDZAKF-UHFFFAOYSA-N 0.000 claims description 2
- DNBSBPRGKGRXBC-UHFFFAOYSA-N N-(5-bromopyridin-2-yl)-2-(2-methoxypyridin-4-yl)pentanamide Chemical compound BrC=1C=CC(=NC1)NC(C(CCC)C1=CC(=NC=C1)OC)=O DNBSBPRGKGRXBC-UHFFFAOYSA-N 0.000 claims description 2
- ISYPFPYFHFXOPM-UHFFFAOYSA-N N-(5-bromopyridin-2-yl)-2-(6-methoxypyridin-3-yl)pentanamide Chemical compound BrC=1C=CC(=NC1)NC(C(CCC)C=1C=NC(=CC1)OC)=O ISYPFPYFHFXOPM-UHFFFAOYSA-N 0.000 claims description 2
- CYCRFWMCYXIXDN-UHFFFAOYSA-N N-(5-bromopyridin-2-yl)-2-[2-(difluoromethoxy)pyridin-4-yl]pentanamide Chemical compound BrC=1C=CC(=NC1)NC(C(CCC)C1=CC(=NC=C1)OC(F)F)=O CYCRFWMCYXIXDN-UHFFFAOYSA-N 0.000 claims description 2
- YEVPBYGVEZWBFI-UHFFFAOYSA-N N-(5-chloro-1,3-thiazol-2-yl)-2-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]pentanamide Chemical compound ClC1=CN=C(S1)NC(C(CCC)C=1C=NC(=CC1)C=1C=NN(C1)C)=O YEVPBYGVEZWBFI-UHFFFAOYSA-N 0.000 claims description 2
- NYQZBFNRYIUGRD-UHFFFAOYSA-N N-(5-chloropyridin-2-yl)-1-(5-chloropyridin-3-yl)cyclobutane-1-carboxamide Chemical compound ClC=1C=CC(=NC1)NC(=O)C1(CCC1)C=1C=NC=C(C1)Cl NYQZBFNRYIUGRD-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010063897 Renal ischaemia Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000021811 Sandhoff disease Diseases 0.000 claims description 2
- 206010069351 acute lung injury Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000006218 bradycardia Diseases 0.000 claims description 2
- 230000036471 bradycardia Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000004410 intraocular pressure Effects 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- CNGSWPZYBNAARL-UHFFFAOYSA-N n-(5-bromopyrazin-2-yl)-2-(5-bromopyridin-3-yl)pentanamide Chemical compound C=1N=CC(Br)=CC=1C(CCC)C(=O)NC1=CN=C(Br)C=N1 CNGSWPZYBNAARL-UHFFFAOYSA-N 0.000 claims 2
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 0 *c1c[n](*)c2c1cc(*)cc2 Chemical compound *c1c[n](*)c2c1cc(*)cc2 0.000 description 5
- YFGUWGSVLLFPDW-UHFFFAOYSA-N 2-(5-bromopyridin-3-yl)pentanoic acid Chemical compound BrC=1C=C(C=NC1)C(C(=O)O)CCC YFGUWGSVLLFPDW-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13195372.1A EP2878339A1 (en) | 2013-12-02 | 2013-12-02 | SIP3 antagonists |
| EP13195372.1 | 2013-12-02 | ||
| PCT/EP2014/075986 WO2015082357A1 (en) | 2013-12-02 | 2014-11-28 | S1p3 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019175781A Division JP2020023512A (ja) | 2013-12-02 | 2019-09-26 | Ｓ１ｐ３アンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539174A JP2016539174A (ja) | 2016-12-15 |
| JP2016539174A5 true JP2016539174A5 (https=) | 2018-01-18 |
| JP6595475B2 JP6595475B2 (ja) | 2019-10-23 |
Family
ID=49674243
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536883A Active JP6595475B2 (ja) | 2013-12-02 | 2014-11-28 | Ｓ１ｐ３アンタゴニスト |
| JP2019175781A Pending JP2020023512A (ja) | 2013-12-02 | 2019-09-26 | Ｓ１ｐ３アンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019175781A Pending JP2020023512A (ja) | 2013-12-02 | 2019-09-26 | Ｓ１ｐ３アンタゴニスト |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9951017B2 (https=) |
| EP (4) | EP2878339A1 (https=) |
| JP (2) | JP6595475B2 (https=) |
| KR (1) | KR102386815B1 (https=) |
| CN (1) | CN106232182B (https=) |
| AU (1) | AU2014359489B2 (https=) |
| CA (1) | CA2932218C (https=) |
| EA (1) | EA034218B1 (https=) |
| NZ (1) | NZ721802A (https=) |
| UA (1) | UA117154C2 (https=) |
| WO (1) | WO2015082357A1 (https=) |
| ZA (1) | ZA201604490B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2878339A1 (en) * | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
| KR102131677B1 (ko) | 2018-03-20 | 2020-08-05 | 주식회사 아하 | 가이드 모듈 및 하폐수 처리용 산기장치 |
| JP7235859B2 (ja) * | 2018-09-17 | 2023-03-08 | ユンジン ファーム．カンパニー、リミテッド | 新規なチアゾール誘導体及びその薬学的に許容される塩 |
| WO2021182914A1 (ko) * | 2020-03-13 | 2021-09-16 | 영진약품 주식회사 | 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염 |
| AU2021359129A1 (en) * | 2020-10-16 | 2023-06-01 | Proxygen Gmbh | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
| WO2023275796A1 (en) * | 2021-07-01 | 2023-01-05 | Novartis Ag | Heterocyclic derivatives as sphingosine-1-phosphate 3 inhibitors |
| JP2025526266A (ja) * | 2022-07-05 | 2025-08-13 | オーリジーン オンコロジー リミテッド | Ｃｄｋ１２／１３阻害剤としての置換ｎ－（ピリジン－２－イル）アセトアミド誘導体 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0081756B1 (en) | 1981-12-14 | 1985-05-15 | MEDEA RESEARCH S.r.l. | New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions |
| EP0946180A4 (en) | 1996-10-07 | 2003-07-23 | Smithkline Beecham Corp | METHODS FOR STIMULATING BONE FORMATION |
| GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| US6320050B1 (en) | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
| KR20020058023A (ko) | 1999-11-18 | 2002-07-12 | 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 | 살충성 아미노헤테로시클릴아미드 화합물 |
| MXPA02010745A (es) | 2000-05-03 | 2003-03-10 | Hoffmann La Roche | Activadores de glucocinasa heteroaromaticos de alquinil-fenilo. |
| JP4742333B2 (ja) | 2000-11-13 | 2011-08-10 | 日本農薬株式会社 | Ｎ−チアジアゾリルシクロプロパンカルボン酸アミド類およびこれを有効成分とする殺虫、殺ダニ剤 |
| DE60117059T2 (de) | 2000-12-06 | 2006-10-26 | F. Hoffmann-La Roche Ag | Kondensierte heteroaromatische glucokinaseaktivatoren |
| EP1424078A4 (en) * | 2001-09-04 | 2009-03-25 | Ono Pharmaceutical Co | RESPIRATORY DISEASE MEDICINES COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATING AGENT |
| PL370989A1 (en) * | 2001-12-21 | 2005-06-13 | Novo Nordisk A/S | Amide derivatives as gk activators |
| TW200307539A (en) | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| EP1501815B1 (en) | 2002-04-26 | 2006-11-22 | F. Hoffmann-La Roche Ag | Substituted phenylacetamides and their use as glucokinase activators |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| US7262196B2 (en) * | 2003-02-11 | 2007-08-28 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| GB0329498D0 (en) * | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| JP4638355B2 (ja) * | 2003-12-26 | 2011-02-23 | 協和発酵キリン株式会社 | チアゾール誘導体 |
| MXPA06008606A (es) | 2004-01-30 | 2007-04-13 | Vertex Pharma | Moduladores de transportadores con casete de union a atp. |
| EP1824835A1 (en) | 2004-12-03 | 2007-08-29 | Novo Nordisk A/S | Heteroaromatic glucokinase activators |
| US7888374B2 (en) * | 2005-01-28 | 2011-02-15 | Abbott Laboratories | Inhibitors of c-jun N-terminal kinases |
| WO2007026761A1 (ja) | 2005-08-31 | 2007-03-08 | Astellas Pharma Inc. | チアゾール誘導体 |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| US8546452B2 (en) * | 2005-10-12 | 2013-10-01 | Toa Eiyo Ltd. | S1P3 receptor antagonist |
| AU2006336504C9 (en) | 2005-12-28 | 2015-05-14 | Vertex Pharmaceuticals Incorporated | 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| EP2049518B1 (en) | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
| US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| WO2008063625A2 (en) * | 2006-11-20 | 2008-05-29 | Adolor Corporation | Pyridine compounds and methods of their use |
| TW200831081A (en) | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| WO2008119734A2 (en) | 2007-03-29 | 2008-10-09 | Novartis Ag | Process for the manufacture of organic compounds |
| US8563594B2 (en) * | 2007-05-08 | 2013-10-22 | Allergan, Inc. | S1P3 receptor inhibitors for treating pain |
| US8969386B2 (en) | 2007-05-09 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| MX2009012678A (es) | 2007-05-25 | 2012-09-20 | Vertex Pharma | Moduladores de canal de ion y metodos de uso. |
| WO2009011850A2 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| JP5287730B2 (ja) | 2008-01-18 | 2013-09-11 | アステラス製薬株式会社 | フェニルアセトアミド誘導体 |
| US8957063B2 (en) | 2008-02-21 | 2015-02-17 | Boehringer Ingelheim International Gmbh | Amine and ether compounds which modulate the CB2 receptor |
| EP2271621B1 (en) | 2008-03-31 | 2013-11-20 | Vertex Pharmaceuticals Incorporated | Pyridyl derivatives as cftr modulators |
| KR20110018366A (ko) * | 2008-05-16 | 2011-02-23 | 다케다 샌디에고, 인코포레이티드 | 글루코키나아제 활성제 |
| AU2009290474A1 (en) | 2008-09-11 | 2010-03-18 | Pfizer Inc. | Heteroaryls amide derivatives and their use as glucokinase activators |
| UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
| WO2011008475A1 (en) * | 2009-06-30 | 2011-01-20 | Allergan, Inc. | Optionally substituted 2-(arylmethyl, aryloxy or arylthio) -n- pyridin-2 -yl-aryl acetamide or 2, 2-bis (aryl) -n-pyridin-2-yl acetamide compounds as medicaments for the treatment of eye diseases |
| US8168795B2 (en) * | 2009-08-11 | 2012-05-01 | Allergan, Inc. | Selective sphingosine-1-phosphate receptor antagonists |
| ES2548683T3 (es) * | 2010-04-23 | 2015-10-20 | Bristol-Myers Squibb Company | Amidas del ácido 4-(5-isoxazolil o 5-pirrazolil-1,2,4-oxadiazol-3-il)-mandélico como agonistas de receptor de esfingosina-1-fosfato 1 |
| JP6097998B2 (ja) * | 2010-12-16 | 2017-03-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成のビアリールアミドインヒビター |
| EP2844733B1 (en) * | 2012-04-18 | 2020-07-15 | Hemoshear, LLC | In vitro model for pathological or physiologic conditions |
| EP2878339A1 (en) * | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
-
2013
- 2013-12-02 EP EP13195372.1A patent/EP2878339A1/en not_active Withdrawn
-
2014
- 2014-11-28 KR KR1020167017929A patent/KR102386815B1/ko active Active
- 2014-11-28 CN CN201480074769.6A patent/CN106232182B/zh active Active
- 2014-11-28 UA UAA201607137A patent/UA117154C2/uk unknown
- 2014-11-28 WO PCT/EP2014/075986 patent/WO2015082357A1/en not_active Ceased
- 2014-11-28 US US15/100,326 patent/US9951017B2/en active Active
- 2014-11-28 CA CA2932218A patent/CA2932218C/en active Active
- 2014-11-28 NZ NZ721802A patent/NZ721802A/en unknown
- 2014-11-28 EA EA201691160A patent/EA034218B1/ru not_active IP Right Cessation
- 2014-11-28 AU AU2014359489A patent/AU2014359489B2/en active Active
- 2014-11-28 EP EP14811790.6A patent/EP3086845B1/en active Active
- 2014-11-28 JP JP2016536883A patent/JP6595475B2/ja active Active
- 2014-11-28 EP EP21155292.2A patent/EP3896068A1/en not_active Withdrawn
- 2014-11-28 EP EP19210115.2A patent/EP3689864A1/en not_active Withdrawn
-
2016
- 2016-07-01 ZA ZA201604490A patent/ZA201604490B/en unknown
-
2018
- 2018-03-16 US US15/923,837 patent/US20180201582A1/en not_active Abandoned
-
2019
- 2019-09-26 JP JP2019175781A patent/JP2020023512A/ja active Pending
-
2020
- 2020-01-24 US US16/751,472 patent/US11472772B2/en active Active
-
2022
- 2022-08-03 US US17/880,577 patent/US20220402875A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539174A5 (https=) | ||
| JP2015508749A5 (https=) | ||
| JP2013505969A5 (https=) | ||
| JP2012532112A5 (https=) | ||
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JP2013537203A5 (https=) | ||
| JP2014051526A5 (https=) | ||
| JP2016501250A5 (https=) | ||
| JP2013508288A5 (https=) | ||
| JP2016040288A5 (https=) | ||
| JP2015500223A5 (https=) | ||
| JP2012508734A5 (https=) | ||
| JP2017511794A5 (https=) | ||
| JP2016512505A5 (https=) | ||
| JP2012530705A5 (https=) | ||
| JP2013525458A5 (https=) | ||
| JP2014507455A5 (https=) | ||
| JP2016520131A5 (https=) | ||
| JP2009532464A5 (https=) | ||
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| JP2012255002A5 (https=) | ||
| JP2016505614A5 (https=) | ||
| JP2017517538A5 (https=) | ||
| JP2017505293A5 (https=) |